Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.24.69 (
botulinum neurotoxin
)
1,901
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
In humans,
botulinum neurotoxin
(
BoNT
) serotype A (BoNT/A) is a useful therapeutic tool, but different
BoNT
serotypes may be useful when a specific immune resistance related to BoNT/A is proved.
BoNT
serotype F (
BoNT
/F) was injected into human muscles but its effects are shorter compared to BoNT/A, whereas
BoNT
serotype B (
BoNT
/B) is effective in humans only if injected at very high doses.
BoNT
serotype C (
BoNT
/C) has a general profile of action similar to BoNT/A. Nevertheless, a comparison between these different BoNTs in human has not yet been reported. To establish the general profile of these different BoNTs in humans and the spread in near and untreated muscles we conducted an electrophysiological evaluation in 12 healthy volunteers by injecting BoNT/A (BOTOX 15MU),
BoNT
/B (NeuroBloc 1500MU),
BoNT
/F (15MU),
BoNT
/C (15MU) and a saline solution (placebo) in the abductor digiti minimi muscle (ADM) in a double-blind manner. The compound muscle action potential (CMAP) amplitude variation, before and at 2, 4, 6 and 8 weeks after the injections, was evaluated in the ADM, the fourth dorsal interosseus, the first dorsal interosseus and the abductor pollicis brevis
APB
. We detected an earlier recovery for
BoNT
/F when compared to the other BoNTs. No significant differences in the local or distant
BoNT
spread was observed among the different serotypes. We conclude that in humans,
BoNT
/B and
BoNT
/C have a general profile similar to BoNT/A and as such these serotypes could be alternative therapies to BoNT/A.
BoNT
/F might be useful when only a short duration of neuromuscular blockade is required.
...
PMID:Different types of botulinum toxin in humans. 1502 55